Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 17 of 17 entries
Sorted by: Best Match Show Resources per page
Cytoreductive Surgery in the Management of Renal Tumours: Rationale, Current Evidence and Future Perspectives.

Indian journal of surgical oncology

Khochikar MV.
PMID: 28127180
Indian J Surg Oncol. 2017 Mar;8(1):33-38. doi: 10.1007/s13193-016-0592-3. Epub 2016 Dec 08.

Renal cell carcinoma accounts for 3% of adult solid malignant tumours. Approximately 25% of the patients present with metastatic disease at presentation. In the era of immunotherapy (interferon alpha-2b and interleukin-2), studies showed significant survival benefit with cytoreductive nephrectomy...

Cite
Khochikar MV. Cytoreductive Surgery in the Management of Renal Tumours: Rationale, Current Evidence and Future Perspectives. Indian J Surg Oncol. 2016;8(1):33-38doi: 10.1007/s13193-016-0592-3.
Khochikar, M. V. (2017). Cytoreductive Surgery in the Management of Renal Tumours: Rationale, Current Evidence and Future Perspectives. Indian journal of surgical oncology, 8(1), 33-38. https://doi.org/10.1007/s13193-016-0592-3
Khochikar, Makarand V. "Cytoreductive Surgery in the Management of Renal Tumours: Rationale, Current Evidence and Future Perspectives." Indian journal of surgical oncology vol. 8,1 (2017): 33-38. doi: https://doi.org/10.1007/s13193-016-0592-3
Khochikar MV. Cytoreductive Surgery in the Management of Renal Tumours: Rationale, Current Evidence and Future Perspectives. Indian J Surg Oncol. 2017 Mar;8(1):33-38. doi: 10.1007/s13193-016-0592-3. Epub 2016 Dec 08. PMID: 28127180; PMCID: PMC5236027.
Copy Download .nbib Format: NLM
Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Lim SG, Yang WL, Ngu JH, Chang J, Tan J, Ahmed T, Dan YY, Lim K, Lee YM, Lee GH, Tan PS, Wai KL, Phyo WW, Khine HHTW, Lee C, Tay A, Chan E.
PMID: 33895361
Clin Gastroenterol Hepatol. 2022 Feb;20(2):e228-e250. doi: 10.1016/j.cgh.2021.04.031. Epub 2021 Apr 22.

BACKGROUND & AIMS: The optimal therapeutic strategy in nucleoside analogue (NA) experienced chronic hepatitis B (CHB) using peginterferon is still unclear; hence we explored a switch to or add-on peginterferon strategy versus continued NA.METHODS: We conducted a randomized controlled...

Cite
Lim SG, Yang WL, Ngu JH, et al. Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT. Clin Gastroenterol Hepatol. 2021;20(2):e228-e250doi: 10.1016/j.cgh.2021.04.031.
Lim, S. G., Yang, W. L., Ngu, J. H., Chang, J., Tan, J., Ahmed, T., Dan, Y. Y., Lim, K., Lee, Y. M., Lee, G. H., Tan, P. S., Wai, K. L., Phyo, W. W., Khine, H. H. T. W., Lee, C., Tay, A., & Chan, E. (2022). Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 20(2), e228-e250. https://doi.org/10.1016/j.cgh.2021.04.031
Lim, Seng Gee, et al. "Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. 20,2 (2022): e228-e250. doi: https://doi.org/10.1016/j.cgh.2021.04.031
Lim SG, Yang WL, Ngu JH, Chang J, Tan J, Ahmed T, Dan YY, Lim K, Lee YM, Lee GH, Tan PS, Wai KL, Phyo WW, Khine HHTW, Lee C, Tay A, Chan E. Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT. Clin Gastroenterol Hepatol. 2022 Feb;20(2):e228-e250. doi: 10.1016/j.cgh.2021.04.031. Epub 2021 Apr 22. PMID: 33895361.
Copy Download .nbib Format: NLM
Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Lim SG, Yang WL, Ngu JH, Chang J, Tan J, Ahmed T, Dan YY, Lim K, Lee YM, Lee GH, Tan PS, Wai KL, Phyo WW, Khine HHTW, Lee C, Tay A, Chan E.
PMID: 33895361
Clin Gastroenterol Hepatol. 2022 Feb;20(2):e228-e250. doi: 10.1016/j.cgh.2021.04.031. Epub 2021 Apr 22.

BACKGROUND & AIMS: The optimal therapeutic strategy in nucleoside analogue (NA) experienced chronic hepatitis B (CHB) using peginterferon is still unclear; hence we explored a switch to or add-on peginterferon strategy versus continued NA.METHODS: We conducted a randomized controlled...

Cite
Lim SG, Yang WL, Ngu JH, et al. Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT. Clin Gastroenterol Hepatol. 2021;20(2):e228-e250doi: 10.1016/j.cgh.2021.04.031.
Lim, S. G., Yang, W. L., Ngu, J. H., Chang, J., Tan, J., Ahmed, T., Dan, Y. Y., Lim, K., Lee, Y. M., Lee, G. H., Tan, P. S., Wai, K. L., Phyo, W. W., Khine, H. H. T. W., Lee, C., Tay, A., & Chan, E. (2022). Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 20(2), e228-e250. https://doi.org/10.1016/j.cgh.2021.04.031
Lim, Seng Gee, et al. "Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. 20,2 (2022): e228-e250. doi: https://doi.org/10.1016/j.cgh.2021.04.031
Lim SG, Yang WL, Ngu JH, Chang J, Tan J, Ahmed T, Dan YY, Lim K, Lee YM, Lee GH, Tan PS, Wai KL, Phyo WW, Khine HHTW, Lee C, Tay A, Chan E. Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT. Clin Gastroenterol Hepatol. 2022 Feb;20(2):e228-e250. doi: 10.1016/j.cgh.2021.04.031. Epub 2021 Apr 22. PMID: 33895361.
Copy Download .nbib Format: NLM
Combined Cytosine-arabinoside plus interferon-alpha .2. Clinical-studies in leukemia and lymphoma.

International journal of oncology

Bezwoda W, Seymour L, Ruff P.
PMID: 21573579
Int J Oncol. 1993 Mar;2(3):469-72. doi: 10.3892/ijo.2.3.469.

Fourteen patients with relapsed refractory hematologic malignancies including 3 patients with AML, 7 with acute blastic CML and 4 patients with NHL were treated with a combination of cytosine arabinoside 100 mg/m2/day plus interferon alpha 2b 10 U/m2/day given...

Cite
Bezwoda W, Seymour L, Ruff P. Combined Cytosine-arabinoside plus interferon-alpha .2. Clinical-studies in leukemia and lymphoma. Int J Oncol. 1993;2(3):469-72doi: 10.3892/ijo.2.3.469.
Bezwoda, W., Seymour, L., & Ruff, P. (1993). Combined Cytosine-arabinoside plus interferon-alpha .2. Clinical-studies in leukemia and lymphoma. International journal of oncology, 2(3), 469-72. https://doi.org/10.3892/ijo.2.3.469
Bezwoda, W, et al. "Combined Cytosine-arabinoside plus interferon-alpha .2. Clinical-studies in leukemia and lymphoma." International journal of oncology vol. 2,3 (1993): 469-72. doi: https://doi.org/10.3892/ijo.2.3.469
Bezwoda W, Seymour L, Ruff P. Combined Cytosine-arabinoside plus interferon-alpha .2. Clinical-studies in leukemia and lymphoma. Int J Oncol. 1993 Mar;2(3):469-72. doi: 10.3892/ijo.2.3.469. PMID: 21573579.
Copy Download .nbib Format: NLM
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

Oncoimmunology

García-Martínez E, Smith M, Buqué A, Aranda F, de la Peña FA, Ivars A, Cánovas MS, Conesa MAV, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 29872569
Oncoimmunology. 2018 Feb 15;7(6):e1433982. doi: 10.1080/2162402X.2018.1433982. eCollection 2018.

Cytokines regulate virtually aspects of innate and adaptive immunity, including the initiation, execution and extinction of tumor-targeting immune responses. Over the past three decades, the possibility of using recombinant cytokines as a means to elicit or boost clinically relevant...

Cite
García-Martínez E, Smith M, Buqué A, et al. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. Oncoimmunology. 2018;7(6):e1433982doi: 10.1080/2162402X.2018.1433982.
García-Martínez, E., Smith, M., Buqué, A., Aranda, F., de la Peña, F. A., Ivars, A., Cánovas, M. S., Conesa, M. A. V., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2018). Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. Oncoimmunology, 7(6), e1433982. https://doi.org/10.1080/2162402X.2018.1433982
García-Martínez, Elena, et al. "Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy." Oncoimmunology vol. 7,6 (2018): e1433982. doi: https://doi.org/10.1080/2162402X.2018.1433982
García-Martínez E, Smith M, Buqué A, Aranda F, de la Peña FA, Ivars A, Cánovas MS, Conesa MAV, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. Oncoimmunology. 2018 Feb 15;7(6):e1433982. doi: 10.1080/2162402X.2018.1433982. eCollection 2018. PMID: 29872569; PMCID: PMC5980390.
Copy Download .nbib Format: NLM
Showing 13 to 17 of 17 entries